"Comparing Weight Loss Drugs: Viking Therapeutics vs. Eli Lilly's GLP-1"

Eli Lilly, a pharmaceutical giant, has a strong track record of success with a lineup of approved medicines and impressive financial results, including the potential blockbuster drug tirzepatide. On the other hand, Viking Therapeutics, a clinical-stage biotech company, has shown promise with positive phase 2 results for its potential weight loss drug VK2735 and has another candidate for non-alcoholic steatohepatitis. While Eli Lilly offers stability and proven success, Viking Therapeutics presents a higher risk but with potential for significant returns.